Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sandoz licenses US rights to Durect's Posimir analgesic for up to $293mm

Executive Summary

Novartis AG's Sandoz International GMBH licensed exclusive US development and marketing rights to Durect Corp.'s local post-operative pain candidate Posimir, an erodible depot formulation of the nonopioid analgesic bupivacaine, which uses Durect's SABER (sucrose acetate isobutyrate extended release) drug delivery system.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies